JP5680536B2 - 組み合わせｇａｓワクチンおよび治療法 - Google Patents

組み合わせｇａｓワクチンおよび治療法 Download PDF

Info

Publication number
JP5680536B2
JP5680536B2 JP2011527423A JP2011527423A JP5680536B2 JP 5680536 B2 JP5680536 B2 JP 5680536B2 JP 2011527423 A JP2011527423 A JP 2011527423A JP 2011527423 A JP2011527423 A JP 2011527423A JP 5680536 B2 JP5680536 B2 JP 5680536B2
Authority
JP
Japan
Prior art keywords
spy0167
protein
spy0416
seq
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011527423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502969A5 (enExample
JP2012502969A (ja
Inventor
アンドレア マネッティ，
アンドレア マネッティ，
サブリナ カポ，
サブリナ カポ，
ジュリアーノ ベンシ，
ジュリアーノ ベンシ，
グランディ，　グイド
グイド グランディ，
イ ロス， イマ マルガリート
イ ロス， イマ マルガリート
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012502969A publication Critical patent/JP2012502969A/ja
Publication of JP2012502969A5 publication Critical patent/JP2012502969A5/ja
Application granted granted Critical
Publication of JP5680536B2 publication Critical patent/JP5680536B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011527423A 2008-09-17 2009-09-17 組み合わせｇａｓワクチンおよび治療法 Active JP5680536B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9755108P 2008-09-17 2008-09-17
US61/097,551 2008-09-17
PCT/IB2009/006949 WO2010076618A1 (en) 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237470A Division JP2015038156A (ja) 2008-09-17 2014-11-25 組み合わせｇａｓワクチンおよび治療法

Publications (3)

Publication Number Publication Date
JP2012502969A JP2012502969A (ja) 2012-02-02
JP2012502969A5 JP2012502969A5 (enExample) 2012-10-25
JP5680536B2 true JP5680536B2 (ja) 2015-03-04

Family

ID=41508998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011527423A Active JP5680536B2 (ja) 2008-09-17 2009-09-17 組み合わせｇａｓワクチンおよび治療法
JP2014237470A Withdrawn JP2015038156A (ja) 2008-09-17 2014-11-25 組み合わせｇａｓワクチンおよび治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014237470A Withdrawn JP2015038156A (ja) 2008-09-17 2014-11-25 組み合わせｇａｓワクチンおよび治療法

Country Status (18)

Country Link
US (2) US20100136041A1 (enExample)
EP (1) EP2344523B1 (enExample)
JP (2) JP5680536B2 (enExample)
CN (1) CN102356090B (enExample)
AU (1) AU2009334428B2 (enExample)
BR (1) BRPI0919236A8 (enExample)
CA (1) CA2737453A1 (enExample)
DK (1) DK2344523T3 (enExample)
ES (1) ES2566740T3 (enExample)
HR (1) HRP20160306T1 (enExample)
HU (1) HUE027618T2 (enExample)
MX (1) MX2011002760A (enExample)
NZ (1) NZ591633A (enExample)
PL (1) PL2344523T3 (enExample)
SI (1) SI2344523T1 (enExample)
SM (1) SMT201600125B (enExample)
WO (1) WO2010076618A1 (enExample)
ZA (1) ZA201102005B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
GB201206366D0 (en) 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
RU2662970C2 (ru) * 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
AU2015246654B2 (en) 2014-04-15 2019-08-08 Griffith University Group A streptococcus vaccine
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
US10329601B2 (en) * 2015-12-28 2019-06-25 Ionian Technologies, Inc. Nicking and extension amplification reaction (NEAR) of Streptococcus species
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
JP7601913B2 (ja) * 2021-01-19 2024-12-17 デンカ株式会社 タンパク質、溶血性連鎖球菌ワクチン、ｄｎａ、ベクター、形質転換体、タンパク質を製造する方法、バキュロウイルス、アグロバクテリウム、ラテックス粒子、キット及び抗ストレプトリジンｏ抗体の測定方法
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827038D0 (en) * 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2008299376B2 (en) * 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
NZ586430A (en) * 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)

Also Published As

Publication number Publication date
PL2344523T3 (pl) 2016-09-30
US20150132337A1 (en) 2015-05-14
AU2009334428A1 (en) 2010-07-08
US20100136041A1 (en) 2010-06-03
BRPI0919236A8 (pt) 2023-01-31
CN102356090A (zh) 2012-02-15
BRPI0919236A2 (pt) 2015-12-15
EP2344523B1 (en) 2016-02-10
SMT201600125B (it) 2016-07-01
JP2015038156A (ja) 2015-02-26
SI2344523T1 (sl) 2016-06-30
CA2737453A1 (en) 2010-07-08
WO2010076618A1 (en) 2010-07-08
DK2344523T3 (da) 2016-04-18
NZ591633A (en) 2012-10-26
ZA201102005B (en) 2016-09-28
HRP20160306T1 (hr) 2016-04-22
HUE027618T2 (en) 2016-11-28
MX2011002760A (es) 2011-06-16
JP2012502969A (ja) 2012-02-02
AU2009334428B2 (en) 2014-02-20
CN102356090B (zh) 2016-01-20
EP2344523A1 (en) 2011-07-20
ES2566740T3 (es) 2016-04-15

Similar Documents

Publication Publication Date Title
JP5680536B2 (ja) 組み合わせｇａｓワクチンおよび治療法
JP5656642B2 (ja) ストレプトリシンｏの変異体形態
US9102741B2 (en) GAS57 mutant antigens and GAS57 antibodies
JP2010508276A (ja) 化膿連鎖球菌のための免疫原性組成物および治療組成物
JP2010538634A5 (enExample)
AU2013203022B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203063A1 (en) Combination gas vaccines and therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150107

R150 Certificate of patent or registration of utility model

Ref document number: 5680536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250